News >

FDA Approves First Flow Cytometry-Based Diagnostic for Blood Cancer Detection

Silas Inman @silasinman
Published: Thursday, Jun 29, 2017

Alberto Gutierrez, PhD

Alberto Gutierrez, PhD

The FDA has approved ClearLLab multicolor reagents (T1, T2, B1, B2, M) for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN). The approval represents the first from the agency for immunophenotyping on a flow cytometer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication